Despite promising clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant opposition from PBMs. These organizations are often building obstacles to coverage, such as steep price requirements and approval processes that hinder user availability. Analysts indicate … Read More